211SK, O’Connor DT (2007) Catecholamine release-inhibitory peptide catestatin (chromogranin
A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in
human autonomic activity and alters risk for hypertension. Circulation 115:2271–2281
Sahu BS, Obbineni JM, Sahu G, Allu PK, Subramanian L, Sonawane PJ, Singh PK, Sasi BK,
Senapati S, Maji SK, Bera AK, Gomathi BS, Mullasari AS, Mahapatra NR (2012) Functional
genetic variants of the catecholamine-release-inhibitory peptide catestatin in an Indian popula-
tion: allele-specific effects on metabolic traits. J Biol Chem 287:43840–43852
Salem RM, Cadman PE, Chen Y, Rao F, Wen G, Hamilton BA, Rana BK, Smith DW, Stridsberg M,
Ward HJ, Mahata M, Mahata SK, Bowden DW, Hicks PJ, Freedman BI, Schork NJ, O’Connor
DT (2008) Chromogranin A polymorphisms are associated with hypertensive renal disease.
J Am Soc Nephrol 19:600–614
Sanchez-Margalet V, Gonzalez-Yanes C, Najib S, Santos-Alvarez J (2010) Metabolic effects and
mechanism of action of the chromogranin A-derived peptide pancreastatin. Regul Pept 161:8–14
Takiyyuddin MA, Parmer RJ, Kailasam MT, Cervenka JH, Kennedy B, Ziegler MG, Lin MC, Li J,
Grim CE, Wright FA et al (1995) Chromogranin A in human hypertension. Influence of hered-
ity. Hypertension 26:213–220
Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD (1986) Pancreastatin, a novel
pancreatic peptide that inhibits insulin secretion. Nature 324:476–478
Theurl M, Schgoer W, Albrecht K, Jeschke J, Egger M, Beer AG, Vasiljevic D, Rong S, Wolf
AM, Bahlmann FH, Patsch JR, Wolf D, Schratzberger P, Mahata SK, Kirchmair R (2010) The
neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-
dependent mechanism. Circ Res 107:1326–1335
Tota B, Angelone T, Mazza R, Cerra MC (2008) The chromogranin A-derived vasostatins: new
players in the endocrine heart. Curr Med Chem 15:1444–1451
Tota B, Gentile S, Pasqua T, Bassino E, Koshimizu H, Cawley NX, Cerra MC, Loh YP, Angelone
T (2012) The novel chromogranin A-derived serpinin and pyroglutaminated serpinin peptides
are positive cardiac beta-adrenergic-like inotropes. FASEB J 26:2888–2898
Tramonti G, Ferdeghini M, Annichiarico C, Norpoth M, Donadio C, Bianchi R, Bianchi C (2001)
Relationship between renal function and blood level of chromogranin A. Ren Fail 23:449–457
Wen G, Mahata SK, Cadman P, Mahata M, Ghosh S, Mahapatra NR, Rao F, Stridsberg M, Smith
DW, Mahboubi P, Schork NJ, O’Connor DT, Hamilton BA (2004) Both rare and common poly-
morphisms contribute functional variation at CHGA, a regulator of catecholamine physiology.
Am J Hum Genet 74:197–207
Winkler H, Fischer-Colbrie R (1992) The chromogranins A and B: the first 25 years and future
perspectives. Neuroscience 49:497–528
Ziegler MG, Kennedy B, Morrissey E, O’Connor DT (1990) Norepinephrine clearance, chromo-
granin A and dopamine beta hydroxylase in renal failure. Kidney Int 37:1357–1362
Chromogranin A SNPs and Disease Association